These results are promising and support testing the combination of MCL1 inhibitors with anti-PD-1, or other ICIs, in advanced melanoma and other cancers that recruit high levels of MDSCs and/or are more sensitive to MCL1 inhibitors themselves. The gene discussed is MCL1; the disease is cancer.